

17W



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.  
Dated: 7-15-04 Signature: Brigitte Crossman  
(Brigitte Crossman)

Docket No.: CDSI-P01-020  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Paul Ashton

Application No.: 10/688151

Confirmation No.: 8861

Filed: October 17, 2003

Art Unit: 3738

For: METHODS FOR MONITORING  
TREATMENT OF DISEASE

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CDSI-P01-020. A duplicate copy of this paper is enclosed.

Dated: July 15, 2004

Respectfully submitted,

By 

Charles Larsen

Registration No.: 48,533

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/688151
				Filing Date	October 17, 2003
				First Named Inventor	Paul Ashton
				Art Unit	3738
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	CDSI-P01-020

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	PETERSON, "Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida", April 2002, Trends-in-Medicine, May 2002, pps 1 - 6		
	CB	PRENTICE, "Surrogate Endpoints in Clinical Trials: Definition and Operational Criteria", Statistics in Medicine, VOL 8, 431-440 (1989)		
	CC	COLBURN, "Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing", J Clin Pharmacol, 2003; 43:329-341		
	CD	COLBURN, "Selecting and Validating Biologic Markers for Drug Development", J Clin Pharmacol, 1997; 37:355-362		
	CE	NEUBAUER, et al, "Comparison of Foveal Thickness Measured with the Retinal Thickness Analyzer and Optical Coherence Tomography", The Journal of Retinal and Vitreous Diseases, May 2001, volume 21, number 6 pps 596-601		
	CF	ANTCLIFF, et al, "Comparison between Optical Coherence Tomography and Fundus Fluorescein Angiography for the Detection of Cystoid Macular Edema in Patients with Uveitis", Ophthalmology, Volume 10, Number 3 pps 593-599, March 2000		
	CG	KONNO, et al, "Retinal Thickness Measurements with Optical Coherence Tomography and the Scanning Retinal Thickness Analyzer", The Journal of Retinal and Vitreous Diseases; 2001, Volume 21, Number 1 pps 57-61		
	CH	GOEBEL, et al, "Retinal Thickness in Diabetic Retinopathy", The Journal of Retinal and Vitreous Diseases, 2002, Volume 22, Number 6, pps 759 - 767		
	CI	KONNO, et al, "Three-Dimensional Analysis of Macular Diseases With a Scanning Retinal Thickness Analyzer and a Confocal Scanning Laser Ophthalmoscope" Department of Ophthalmology, Asahikawa Medical College, Asahikawa, Japan, June 2000		
	CJ	OSHIMA, et al, "Quantitative Assessment of Macular Thickness in Normal Subjects and Patients with Diabetic Retinopathy by Scanning Retinal Thickness and Analyser", Br J Ophthalmol 1999;83:54-61		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--